U.S. orders $690M in swine-flu vaccine from Novartis, $71M from GSK - San Francisco Business Times:

http://myeclass.net/27.htm
The money will be used to placee additional orders on existing contracts with vaccined manufacturers includingand . The former facility in Emeryvillr is now ownedby Novartis. The government is placinh orders for antigenand adjuvant. Antigen is the active ingredient in a vaccind that triggers the immune system to developo antibodies to fight theH1N1 virus. Adjuvant is addex to boost the immune syste and reduce the amount of antigen needede forthe vaccine. The vaccine ingredients will become a part of the pandemic stockpile, for use if a vaccination campaign is necessary.
Swiss companhy Novartis (NYSE: NVS), which is buildinfg a vaccine manufacturing facility in Holly received an orderfor $346 million for antigeb and $343.8 million for adjuvant. London-based GlaxoSmithKlinew (NYSE: GSK) received an order for $71.4 million of adjuvant. In addition, received a $61.4 millionn order for antigen, and MedImmune won a $61 millioh order for its nasalflu spray. “Wed are doing our part to be as prepared as possible for the impacg that this infectious disease could have on our Health and Human Services Secretary Kathleen Sebelius said ina “Vaccines may serve an important role in that